Patrick W. Serruys1,2,3, MD, PhD; Ahmed Elkoumy1,2, MD; Scot Garg4, MD, PhD
1. Department of Cardiology, University of Galway, Galway, Ireland; 2. Corrib Core Lab, University of Galway, Galway, Ireland; 3. CÚRAM, SFI Research Centre for Medical Devices, Galway, Ireland; 4. Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK
These iconic movie characters share one common trait with the ACURATE neo2 (Neo2): resilience − the ability to become stronger, better, and more successful − even after a setback.
In the randomised SCOPE I trial1, the self-expanding (SE) ACURATE neo (Neo; Boston Scientific) failed to meet non-inferiority against the balloon-expandable (BE) SAPIEN 3 (S3; Edwards Lifesciences) due to significant paravalvular leak (PVL). In SCOPE II2, the Neo failed against the CoreValve Evolut (Medtronic), with significantly higher rates of PVL and cardiac death at 30 days2. The causes of failure were targeted by adding 2 main features to the Neo: a newly designed ...